文献速递乳腺癌放疗

乳腺肿瘤伴腋窝软组织内血管内肿瘤栓子:复发风险与放射治疗结局

Breast Cancer Presenting With Intravascular Tumor Emboli in Axillary Soft Tissue: Recurrence Risk and Radiation Therapy Outcomes.
PubMed 文献 · Adv Radiat Oncol · 2024-04-15

该研究基于1992至2020年前瞻性维护数据库,分析乳腺肿瘤伴腋窝软组织血管内肿瘤栓子(ITE)患者的复发风险及放疗价值。将ITE患者按倾向评分1:2匹配无ITE患者后,两组5年局部区域复发、远处复发、总生存和无病生存均无显著差异;但在ITE患者中,接受放疗与无病生存显著改善相关(HR 0.34,95%CI 0.12-0.93,P=0.04)。作者认为需更大样本和更长随访评估ITE的预后与预测意义。

要点

  • ITE患者与匹配无ITE患者5年局部区域复发无显著差异(5.4% vs 10%,P=0.53)。
  • ITE患者与匹配无ITE患者5年远处复发无显著差异(24% vs 21%,P=0.51)。
  • ITE患者中接受放疗与无病生存显著改善相关(HR 0.34,95%CI 0.12-0.93,P=0.04)。

核心结论

  • 伴ITE的乳腺肿瘤患者与倾向评分匹配的无ITE队列相比,局部区域复发、远处复发、无病生存和总生存均无显著差异。
  • 在ITE患者中,接受放疗者无病生存显著改善。
  • 作者认为需更大样本和更长随访评估ITE的预后与预测意义。

研究设计与样本

  • 分析1992至2020年前瞻性维护的乳腺肿瘤患者数据库。
  • 共2377例患者,其中129例有ITE,126例ITE患者按倾向评分1:2匹配至252例无ITE患者。
  • 采用竞争风险方法评估局部区域复发和远处复发,以死亡为竞争事件。
  • 采用Cox回归模型评估总生存和无病生存。
  • 在ITE患者中评估放疗是否改善结局。

主要发现

  • 自手术起中位随访5.5年(IQR 2.3-9.7)。
  • 5年局部区域复发:ITE组5.4%(95%CI 1.6%-13%)vs 无ITE组10%(95%CI 6.7%-15%),P=0.53。
  • 5年远处复发:ITE组24%(95%CI 15%-35%)vs 无ITE组21%(95%CI 16%-27%),P=0.51。
  • 5年总生存和无病生存两组无差异(两项比较均P>0.9,ITE组vs无ITE组)。
  • ITE患者中接受放疗与无病生存显著改善相关(HR 0.34,95%CI 0.12-0.93,P=0.04)。

关键数值与推荐

  • ITE定义为腋窝软组织内血管内肿瘤栓子。
  • 倾向评分匹配比例为ITE患者1:2匹配无ITE患者。
  • 放疗与无病生存改善的HR为0.34(95%CI 0.12-0.93,P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需更大样本和更长随访的研究评估ITE的预后与预测意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravascular tumor emboli in axillary soft tissue (ITE) is a rare pathologic finding in breast cancer and is associated with higher axillary nodal disease burden. The independent prognostic and predictive value of this entity is unknown, as is the role of radiation therapy for ITE. METHODS AND MATERIALS: We analyzed a prospectively maintained database of breast cancer patients treated from 1992 to 2020. Patients with ITE were matched to those without (1:2) based on propensity scores to control for potential confounding factors. Locoregional (LRR) and distant recurrence (DR) were evaluated using competing risks methods accounting for death as a competing event. Overall survival (OS) and disease-free survival (DFS) were evaluated by Cox regression models. Among patients with ITE, we also evaluated whether RT improved outcomes. RESULTS: Among 2377 total patients, 129 had ITE, of whom 126 were propensity score matched to 252 without ITE. Median follow-up from time of surgery was 5.5 years (IQR 2.3, 9.7). There were no statistically significant differences in the 5-year incidence of LRR between groups (5.4% [95% CI, 1.6%-13%] with ITE vs 10% [95% CI, 6.7%-15%] without, P = .53) or DR (24% [95% CI, 15% 35%] with ITE vs 21% [95% CI, 16%-27%] without, P = .51). Five-year OS and DFS did not differ between groups (P > .9 for both comparisons, patients with ITE vs without ITE). In analyzing the effect of RT among patients with ITE, receipt of RT was associated with significantly improved DFS (HR, 0.34, 95% CI, 0.12-0.93, P = .04). CONCLUSIONS: Patients with ITE do not exhibit significantly worse LRR, DR, DFS, or OS compared with a propensity-score-matched cohort without ITE. However, among patients with ITE, those who received RT demonstrated significantly improved DFS. Larger studies with longer follow-up are needed to evaluate the prognostic and predictive implications of ITE.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sarkar RR, Lavery JA, Zhang Z, et al. Breast Cancer Presenting With Intravascular Tumor Emboli in Axillary Soft Tissue: Recurrence Risk and Radiation Therapy Outcomes. Adv Radiat Oncol. 2024. PMID: 38799109. doi:10.1016/j.adro.2024.101508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。